1. Home
  2. XLO vs ORGS Comparison

XLO vs ORGS Comparison

Compare XLO & ORGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • ORGS
  • Stock Information
  • Founded
  • XLO 2016
  • ORGS 2008
  • Country
  • XLO United States
  • ORGS United States
  • Employees
  • XLO N/A
  • ORGS N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • ORGS Biotechnology: Pharmaceutical Preparations
  • Sector
  • XLO Health Care
  • ORGS Health Care
  • Exchange
  • XLO Nasdaq
  • ORGS Nasdaq
  • Market Cap
  • XLO 36.2M
  • ORGS 24.9M
  • IPO Year
  • XLO 2021
  • ORGS N/A
  • Fundamental
  • Price
  • XLO $0.79
  • ORGS $3.25
  • Analyst Decision
  • XLO
  • ORGS
  • Analyst Count
  • XLO 0
  • ORGS 0
  • Target Price
  • XLO N/A
  • ORGS N/A
  • AVG Volume (30 Days)
  • XLO 115.0K
  • ORGS 31.5K
  • Earning Date
  • XLO 11-07-2024
  • ORGS 11-11-2024
  • Dividend Yield
  • XLO N/A
  • ORGS N/A
  • EPS Growth
  • XLO N/A
  • ORGS N/A
  • EPS
  • XLO N/A
  • ORGS N/A
  • Revenue
  • XLO $2,357,000.00
  • ORGS $662,000.00
  • Revenue This Year
  • XLO N/A
  • ORGS $13,429.43
  • Revenue Next Year
  • XLO $383.35
  • ORGS N/A
  • P/E Ratio
  • XLO N/A
  • ORGS N/A
  • Revenue Growth
  • XLO N/A
  • ORGS N/A
  • 52 Week Low
  • XLO $0.49
  • ORGS $2.50
  • 52 Week High
  • XLO $2.89
  • ORGS $10.80
  • Technical
  • Relative Strength Index (RSI)
  • XLO 49.80
  • ORGS 35.76
  • Support Level
  • XLO $0.75
  • ORGS $2.76
  • Resistance Level
  • XLO $0.84
  • ORGS $3.49
  • Average True Range (ATR)
  • XLO 0.06
  • ORGS 0.38
  • MACD
  • XLO 0.01
  • ORGS -0.01
  • Stochastic Oscillator
  • XLO 56.83
  • ORGS 22.13

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About ORGS Orgenesis Inc.

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Share on Social Networks: